11 February 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, today announced the scheduled retirement of its Chief Financial Officer, Ms Lori Milbrandt, and the appointment of Mr Jonathon Gut as the incoming Chief Financial Officer.
Ms Milbrandt will remain in the role until 30 June 2022, and Mr Gut will assume the role on 1 July 2022. Ms Milbrandt has served as the Company’s Chief Financial Officer since 2007.
Imricor’s Chair and CEO, Steve Wedan, said: “It’s not enough to say that Lori has been a highly valued senior leader at Imricor. She has become, in fact, a dear friend. During the past 15 years, she has made a significant contribution to the business through many phases including startup, IPO, and early commercialization. She has built a strong team around her who draw from her extensive experience as a financial leader in the medical device field, and I would like to thank her for her dedication and commitment to the organization, its people, and our mission. We all wish Lori the very best in her retirement.”
Mr Gut joined the Company in August 2020 as the Controller, and in May 2021 was appointed as Imricor’s Director of Finance, in addition to retaining his role as Controller for the Company. Mr Gut has over 13 years of accounting and finance experience, the last 10 of them in the medical device industry, having previously worked for both private and publicly owned companies, including Galil Medical and Boston Scientific.
Imricor’s Chair and CEO, Steve Wedan, said: “Jon is perfect for this role, and I am pleased to welcome him as our new Chief Financial Officer starting in July. Jon has proven himself to be a strong strategic thinker, a great teammate, and a person of the highest integrity. No one knows more about our business and no one is better suited to help lead us into the future than Jon.
“Over the next several months, we will enjoy a lengthy transition period, ensuring a smooth and gradual hand-off of responsibilities from Lori to Jon, and no disruption to our operations. I am looking forward to working closely with Jon in the coming years as we continue to deliver on our strategic goals of growing our site base, expanding our indications for use, and broadening our geographic reach.”